EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability

Alireza Nomani iD, Aishwarya Saraswat, Heather Brown, Jimmy Chun-Tien Kuo, Huu Thuy Trang Duong, Jikang Wu iD, Yu Zhang, Yue Fu, Youmi Moon, Shafiq Wahidi, Nancy Mejia, Suzanne Hartford und 4 weitere

Nanomaterials · 18.02.2026 · 16 (4) · 268

DOI: 10.3390/nano16040268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 18.02.2026. Verfasst von Alireza Nomani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The long-term stability of mRNA-lipid nanoparticles (LNPs), essential for mRNA vaccines and gene therapies, relies on managing physicochemical properties to preserve their integrity and effectiveness through optimized formulation components. This study systematically evaluated LNP formulations with varied compositions, e.g., Dlin-MC3-DMA and ALC-0315 as ionizable lipids, and DMG-PEG2k or ALC-0159 as polyethylene glycol (PEG)-lipids, stored at −80 °C, −20 °C, 5 °C, and 25 °C in Tris buffer (pH 7.4) for 12 months.

Methods

Sixteen quality attributes were analyzed, including particle size, mRNA encapsulation, lipid oxidation, and transfection efficiency over different formulations and storage temperatures to mechanistically evaluate the long-term stabilities.

Results

Formulations stored at −80 °C and −20 °C retained acceptable stability, while storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation. Storage at 25 °C led to complete loss of transfection within six months. Mechanistic studies identified oxidative and hydrolytic lipid degradation (e.g., DSPC) in ALC-0315 formulations and MC3 N-oxidation with subvisible particulates in MC3-containing LNPs as primary failure modes. Increasing Tris buffer concentration accelerated 5′-cap hydrolysis, emphasizing the importance of a low-ionic-strength buffer for LNP formulations.

Conclusions

Findings re-emphasize the necessity of deep-cold storage (≤−20 °C) and optimized formulation components to preserve mRNA–LNP integrity, offering insights for designing next-generation LNPs with improved shelf-life.

Schlagwörter

Stichwörter der Autor:innen

ALC-0315MC3buffer ionic strengthlipid nanoparticles (LNPs)lipid oxidationlong-term stabilitymRNAquality attributes

Autor:innen und Institutionen

  • Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Regeneron Genetic Medicines, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Analytical & Biological Mass Spectrometry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Product Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.

ORCID-Profile: Alireza Nomani, Jikang Wu, Haibo Qiu

Zitieren

APA

Nomani, A., Saraswat, A., Brown, H., Kuo, J. C., Duong, H. T. T., Wu, J., Zhang, Y., Fu, Y., Moon, Y., Wahidi, S., Mejia, N., Hartford, S., Qiu, H., Rayaprolu, B., Bhalla, A. S., & Shameem, M. (2026). Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability. Nanomaterials, 16(4), 268. https://doi.org/10.3390/nano16040268

Vancouver

Nomani A, Saraswat A, Brown H, Kuo JC, Duong HTT, Wu J, et al. Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability. Nanomaterials. 2026;16(4):268. doi:10.3390/nano16040268

BibTeX
@article{Nomani2026,
  author = {Nomani, Alireza and Saraswat, Aishwarya and Brown, Heather and Kuo, Jimmy Chun-Tien and Duong, Huu Thuy Trang and Wu, Jikang and Zhang, Yu and Fu, Yue and Moon, Youmi and Wahidi, Shafiq and Mejia, Nancy and Hartford, Suzanne and Qiu, Haibo and Rayaprolu, Bindhu and Bhalla, Amardeep S and Shameem, Mohammed},
  title = {Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability},
  journal = {Nanomaterials},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {268},
  doi = {10.3390/nano16040268}
}
Kostenlos starten →